Synthetic Biologics reports positive Ph2b data of CDI in patients with LRTIs on IV beta lactam antibiotics
On Thursday, Synthetic Biologics reported positive results from their Ph2b trial evaluating the emergence of C. diff infection (CDI) in patients with lower respiratory tract infections (LRTIs) on beta lactam antibiotics.
The data demonstrated a significant decrease in the likelihood of CDI in patients on intravenous (IV) beta lactam antibiotics. Overall, patients taking SYN-004 had a 71% relative risk reduction compared to placebo. While SYN-004 did not reach statistical significance with overall antibiotic-associated diarrhea, there was a trend indicative of efficacy. Furthermore, SYN-004 significantly reduced the emergence of new vancomycin-resistant enterococci (VRE). It is worth noting that an additional analysis will evaluate antibiotic resistance and will be reported later this year. Synthetic Biologics will be giving a presentation at Biotech Showcase 2017 on Monday Jan. 9th at which time the data will be further elaborated.
Synthetic Biologics (SYN) is one of Amp Biotech Research's quarterly picks for Q1 2017. Amp is a biotech research firm that publishes a quarterly list of companies with attractive valuations and near-term catalysts. To see all of Amp's picks for Q1 2017, go to www.ampbioresearch.com.
Find the press release here: http://www.syntheticbiologics.com/news-media/press-releases/detail/230/synthetic-biologics-syn-004-ribaxamase-achieves-primary